Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Southwest Airlines Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.05 (market cap $29.60B), while Southwest Airlines Co trades at $44.99 (market cap $22.27B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Southwest Airlines Co pays a 1.58% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LUV | |
|---|---|---|
Market Cap | $29.60B | $22.27B |
Sector | Health | Industrials |
52-Week High | $491.22 | $54.80 |
52-Week Low | $205.48 | $29.67 |
Enterprise Value | $27.56B | $25.37B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Southwest Airlines (LUV) trades at $44.9, down 4.57% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while revenue growth is projected to rise to $30.1B in 2026. Recent news highlights board appointments and initiatives to attract business travelers, amid a volatile fuel cost environment.
LUV presents a cautious opportunity with a consensus price target of $53.86 implying upside, supported by improving cash flow and dividend payments. Risks include fuel price volatility, execution on new business offerings, and competitive pressures, requiring careful monitoring of earnings consistency and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
